摘要:
The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I); wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc.; R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要:
The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I): wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc.; R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要:
The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译:本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。 一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物,其包含式(I)化合物:其中环A是取代或未取代的5至7元环烷烃,取代或未取代的5至7元环烯烃或 喜欢; C是碳原子; -X-是-N(R 16) - 等; R 16是氢,取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基,取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-,-S-等; R6是取代或未取代的环烷基,取代或未取代的环烯基等; R2是氢,羟基等,或其药学上可接受的盐或其溶剂合物。
摘要:
The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要:
The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译:本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。 一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物,其包含式(I)化合物:其中环A是取代或未取代的5至7元环烷烃,取代或未取代的5至7元环烯烃或 喜欢; C是碳原子; -X-是-N(R 16) - 等; R 16是氢,取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基,取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-,-S-等; R6是取代或未取代的环烷基,取代或未取代的环烯基等; R2是氢,羟基等,或其药学上可接受的盐或其溶剂合物。
摘要:
The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I): wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ═Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
摘要:
The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I); wherein Ra, Rb and Rc are, (a) Ra and Rb are taken together ═Z; and Rc is a group represented by R1c; or (b) Rb and Rc are taken together to form a bond; and Ra is a group represented by —Y—R1a; R1a and R1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R2 and R3 are each independently substituted or unsubstituted aryl, etc.; R4a and R4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R5)—, etc.; R5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
摘要:
A load abnormality detecting system and method for detecting the burnout and short circuit of a load are provided. A voltage generator (10) generates a specified voltage Vs in accordance with a load current IL. A judging device (4) compares a signal corresponding to this voltage (Vs) with a specified reference value (T1, T2) to judge whether a load (2) has any abnormality. A selector (6) causes the burnout reference value (T1) to be inputted to the judging device (4) and controls the voltage generator (10) to use a first resistance value when checking the burnout of the load (2) while causing the short-circuit reference value (T2) to be inputted to the judging device (4) and controlling the voltage generator (10) to use a second resistance value when checking the short circuit of the load (2).
摘要:
A load abnormality detecting system and method for detecting the burnout and short circuit of a load are provided. A voltage generator (10) generates a specified voltage Vs in accordance with a load current IL. A judging device (4) compares a signal corresponding to this voltage (Vs) with a specified reference value (T1, T2) to judge whether a load (2) has any abnormality. A selector (6) causes the burnout reference value (T1) to be inputted to the judging device (4) and controls the voltage generator (10) to use a first resistance value when checking the burnout of the load (2) while causing the short-circuit reference value (T2) to be inputted to the judging device (4) and controlling the voltage generator (10) to use a second resistance value when checking the short circuit of the load (2).
摘要:
A method for assembling a motor vehicle body by fixing relative positional relationship among a plurality of motor vehicle body constituent parts by means of positioning members provided in a welding jig which is disposed on each side of an assembly station and, in this condition, welding together the plurality of motor vehicle body constituent parts at a plurality of tack-welding locations. First welding guns of indirect feeding type are mounted on the welding jig to weld a part of the tack-welding portions. A welding robot having mounted thereon a second welding gun is disposed outside the welding jig. The above-described part of the tack-welding portions are welded by supplying electric power from the second welding gun to the first welding guns by pinching, by the second welding gun, feeder terminals of the first welding guns in a condition in which the above-described part of the tack-welding portions are being pinched by the first welding guns. The remaining of the tack-welding portions are thereafter welded by the second welding gun.